Justin G. Stroh
Pfizer
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Justin G. Stroh.
Gene | 1994
George Coppola; Yan Yan; Petros Hantzopoulos; Edy Segura; Justin G. Stroh; David H. Calhoun
Fabry disease is an X-linked inborn error of glycolipid metabolism caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (GalA; EC 3.2.1.22). In order to obtain large quantities of this human enzyme for physical characterization and for the development of new approaches for enzyme therapy, we constructed derivatives of the Autographa californica nuclear polyhedrosis virus that produce the human enzyme. The recombinant GalA (re-GalA) is produced at high levels, and is active with both the artificial substrate, 4-methylumbelliferyl-alpha-D-galactopyranoside, and the natural in vivo substrate, trihexosylceramide. The purified re-GalA is glycosylated and is taken up by normal and Fabry fibroblasts in cell culture. Mass spectral analysis of total monosaccharides released by hydrazinolysis indicates that it contains fucose, galactose, mannose and N-acetylglucosamine. Amino-acid sequence analysis of six proteolytic peptides corresponded to sequences predicted by the cDNA. The molecular masses of the purified enzyme, estimated by electrospray mass spectroscopy and laser desorption time-of-flight analysis are 46.85 and 46.62 kDa, respectively, approx. 10% greater than the polypeptide portion predicted by the cDNA. The recombinant enzyme retains significant catalytic activity after modification with poly(ethylene glycol), a treatment which decreases the immunogenicity and increases the circulation life of many proteins used therapeutically.
Biochemical Pharmacology | 2012
Krisztina M. Papp-Wallace; Christopher R. Bethel; Thomas D. Gootz; Wenchi Shang; Justin G. Stroh; William Lau; Dale McLeod; Loren M. Price; Anthony Marfat; Anne M. Distler; Sarah M. Drawz; Hansong Chen; Emily Harry; Micheal Nottingham; Paul R. Carey; John D. Buynak; Robert A. Bonomo
β-Lactamase inhibitors (clavulanic acid, sulbactam, and tazobactam) contribute significantly to the longevity of the β-lactam antibiotics used to treat serious infections. In the quest to design more potent compounds and to understand the mechanism of action of known inhibitors, 6β-(hydroxymethyl)penicillanic acid sulfone (6β-HM-sulfone) was tested against isolates expressing the class A TEM-1 β-lactamase and a clinically important variant of the AmpC cephalosporinase of Pseudomonas aeruginosa, PDC-3. The addition of the 6β-HM-sulfone inhibitor to ampicillin was highly effective. 6β-HM-sulfone inhibited TEM-1 with an IC(50) of 12 ± 2 nM and PDC-3 with an IC(50) of 180 ± 36 nM, and displayed lower partition ratios than commercial inhibitors, with partition ratios (k(cat)/k(inact)) equal to 174 for TEM-1 and 4 for PDC-3. Measured for 20 h, 6β-HM-sulfone demonstrated rapid, first-order inactivation kinetics with the extent of inactivation being related to the concentration of inhibitor for both TEM-1 and PDC-3. Using mass spectrometry to gain insight into the intermediates of inactivation of this inhibitor, 6β-HM-sulfone was found to form a major adduct of +247 ± 5 Da with TEM-1 and +245 ± 5 Da with PDC-3, suggesting that the covalently bound, hydrolytically stabilized acyl-enzyme has lost a molecule of water (HOH). Minor adducts of +88 ± 5 Da with TEM-1 and +85 ± 5 Da with PDC-3 revealed that fragmentation of the covalent adduct can result but appeared to occur slowly with both enzymes. 6β-HM-sulfone is an effective and versatile β-lactamase inhibitor of representative class A and C enzymes.
Journal of Chromatography A | 1994
Kenneth J. Rosnack; Justin G. Stroh; David H. Singleton; Bradley C. Guarino; Glenn C. Andrews
We have constructed a capillary electrophoresis (CE) system with UV detection and have successfully interfaced it to an electrospray ionization mass spectrometry (ES-MS) system. A synthesized fragment of heregulin-beta (212-226) was thought to be a single component by re-injection into an HPLC system, but results from CE-UV-ES-MS indicated that a dehydration product was present in the desired peptide sample. A synthetic heregulin-alpha (177-241) was isolated by preparative HPLC, but re-injection on an analytical system indicated a tailing peak. CE-UV-ES-MS indicated a mixture whose two major components were of the same nominal molecular mass (within experimental error), suggesting the presence of an isomer or a deamidation product. The results show that CE-UV-ES-MS can be used as an orthogonal analytical technique to solve practical problems encountered in peptide synthesis laboratories.
Journal of Separation Science | 2008
Justin G. Stroh; Christopher Petucci; Scott J. Brecker; Lisa M. Nogle
Recent advances in accurate mass analysis are poised to allow the high-throughput production of accurate mass data on many more compounds than was previously available. It is shown that sub-ppm mass accuracy (producing elemental compositions) can be obtained on a simple TOF mass spectrometer operating in the manufacturers standard mode. Concomitantly, there have been important technological advances in LC with respect to speed of analysis using sub-2 microm particle columns. Much of the sub-2 microm work in the literature has been under the label ultra performance LC (UPLC), however, we show that very high-speed results can be obtained using other manufacturers pumps by using elevated column temperatures. Using elevated temperatures, HPLC peak widths on the order of 1 s can be obtained. We report the coupling of these two technologies (sub-ppm mass accuracy MS with high-speed HPLC) for the rapid analysis of compounds entering pharmaceutical libraries.
Analytical and Bioanalytical Chemistry | 2014
Suk-Joon Hyung; Xidong Feng; Ye Che; Justin G. Stroh; Michael Shapiro
AbstractCyclosporin is a family of neutral cyclic undecapeptides widely used for the prevention of organ transplant rejection and controlling viral infection. The equilibrium of conformations assumed by cyclosporin A in response to the solvent environment is thought to play a critical role in enabling good membrane penetration, which improves upon shielding the polarity of the molecule through forming intramolecular hydrogen bonds. However, the distribution of structures and their internal hydrogen bond geometries have not been elucidated thus far across the series of cyclosporins. Herein, we elucidate the conformational heterogeneity of cyclosporins using a set of analytical approaches including ion mobility mass spectrometry, hydrogen–deuterium exchange, and molecular dynamics simulation. Ion mobility measurements reveal a specific conformational distribution for each cyclosporin derivative in a structure-dependent manner. In general, we observe that the more compact conformer is associated with a greater frequency of intramolecular hydrogen bonds. Cyclosporin A is populated by structures with an extensive hydrogen bond network that is lacking in cyclosporin H, which is composed predominantly of a single compact conformation. The slower dynamics of cyclosporin H backbone is also consistent with the lack of hydrogen bonds. Furthermore, we find a strong correlation between the steric bulk of the side chain at position 2 of cyclosporin and the distribution of conformers due to differential accommodation of side chains within the macrocycle, and also report a wide range of conformational dynamics in solution.n FigCyclosporin analogues display distinct conformation types with different hydrogen bonding arrangements
Archive | 1994
Justin G. Stroh; Kenneth L. Rinehart
The fast atom bombardment (FAB) ionization technique,(1) introduced in 1981, opened new vistas in the analysis of compounds previously intractable to mass spectrometry (MS). Before its introduction, compounds that were polar or thermally unstable required laborious and difficult derivatization prior to mass spectral analysis. Although derivatization often produced compounds that were observable by electron ionization (EI) or chemical ionization (CI), the spectra were complex. FABMS, with no derivatization required, yields simpler and more easily interpretable spectra; since its introduction, FABMS has become the method of choice for polar compounds. Probe FABMS is fundamentally different from such ionization techniques as EI and CI in that FAB is a desorption technique. With FABMS, the analyte is dissolved or dispersed in a polar matrix [e.g., glycerol, thioglycerol, m-nitrobenzyl alcohol, diethanolamine, or a liquid mixture of dithiothreitol and dithioerythritol (“magic bullet”)],(2) and the mixture is applied to a probe target. The target is inserted into the ion source of the mass spectrometer where its surface is bombarded with high-energy (8–10 keV) atoms [or in matrix secondary ion (SI)MS, with ions]. Cation attachment to, or proton removal from, the analyte occurs, producing ions that can then be analyzed in the mass spectrometer. Not only are molecular ion species produced, but often structurally useful fragment ions as well. Although FABMS is simple in design, it works best if the analyte is pure, unless tandem mass spectrometry (MS/MS) is used to study mixtures’ individual components. The surface activity of impurities or other components can be a problem with FABMS, and their removal or separation is often carried out by using high-performance liquid chromatography (HPLC).
Bioconjugate Chemistry | 1992
Kieran F. Geoghegan; Justin G. Stroh
Analytical Biochemistry | 1999
Kieran F. Geoghegan; Henry B. F. Dixon; Philip J. Rosner; Lise R. Hoth; Anthony J. Lanzetti; Kris A. Borzilleri; Eric S. Marr; Linda H. Pezzullo; LeRoy B. Martin; Peter K. LeMotte; Alexander S. McColl; Ajith V. Kamath; Justin G. Stroh
Biochemistry | 2004
Bruce R. Branchini; Tara L. Southworth; Martha H. Murtiashaw; Rachelle A. Magyar; Susan A. Gonzalez; Maria C. Ruggiero; Justin G. Stroh
Journal of Biological Chemistry | 1995
Elsa G. Barbacci; Bradley C. Guarino; Justin G. Stroh; David H. Singleton; Kenneth J. Rosnack; James D. Moyer; Glenn C. Andrews